A practical reference on Ion pairing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
=== Individualization Phase === Students may complete courses in Individualization Phase, often referred to as the "Indy" Phase, at any of the University of North Carolina School of Medicine campuses or sites. In this phase, the final year of their medical education, students take a variety of elective courses designed to tailor their education toward the specialty they plan to pursue. The phase also includes support for students’ transition into residency.
== Contents == A 1958 source describes Dover's Powder as follows: "Powder of Ipecacuanha and Opium (B.P., Egyp. P., Ind. P.). Pulv. Ipecac. et Opii; Ipecac and Opium Powder (U.S.N.F.); Dover's Powder; Compound Ipecacuanha Powder. Prepared ipecacuanha, 10 g., powdered opium 10 g., lactose 80 g. It contains 1% of anhydrous morphine. Dose: 320 to 640 mg. (5 to 10 grains). Many foreign pharmacies include a similar powder, sometimes with potassium sulphate or with equal parts of potassium nitrate and potassium sulphate in place of lactose; max. single dose 1 to 1.5 g. and max. in 24 hours 4 to 6 g."
As such, it appears that there may be species differences in the central penetration of bicalutamide and that the medication does indeed cross the blood–brain barrier and affect central function in humans. This is supported by potential side effects of bicalutamide, in spite of increased testosterone levels, like hot flashes and decreased sexual interest in men. However, a clinical study comparing bicalutamide and flutamide in men found that bicalutamide had less influence on the HPG axis than flutamide, suggesting that bicalutamide might have a limited degree of peripheral selectivity, at least compared to other NSAAs, in humans. Bicalutamide has been identified as a substrate of P-glycoprotein and of the breast cancer resistance protein (BCRP), though not of the multidrug resistance-associated protein 1 (MRP1). This may be involved in tumor resistance to bicalutamide. P-Glycoprotein is also known to play a major role in excluding drugs from the brain due to efflux back across the blood–brain barrier. It is known that there are prominent species differences in the role of P-glycoprotein in limiting permeation of P-glycoprotein substrates across the blood–brain barrier.
The meteorite contained a mixture of left-handed and right-handed amino acids; most amino acids used by living organisms are left-handed in chirality, and most sugars used are right-handed. A team of chemists in Sweden demonstrated in 2005 that this homochirality could have been triggered or catalyzed by the action of a left-handed amino acid such as proline. Several lines of evidence indicate that the interior portions of well-preserved fragments from Murchison are pristine. A 2010 study using high resolution analytical tools including spectroscopy, identified 14,000 molecular compounds, including 70 amino acids, in a sample of the meteorite. The limited scope of the analysis by mass spectrometry provides for a potential 50,000 or more unique molecular compositions, with the team estimating the possibility of millions of distinct organic compounds in the meteorite. In November 2019, along with the Northwest Africa 801 meteorite it was the first to provide evidence of pentoses (including ribose) in space, using gas chromatography–mass spectrometry. All the straight-chain five-carbon aldoses were found but tetroses, sugar alcohols, sugar acids, and deoxyribose were not detected. In 2020, NASA announced that hexamethylenetetramine had been found in the Murchison, Murray and Tagish Lake meteorites.
Layne Staley – lead and backing vocals, rhythm guitar on "Hate to Feel" and "Angry Chair"; sun logo/icons Jerry Cantrell – guitars, backing vocals, co-lead vocals on "Down in a Hole" and "Would?" Mike Starr – bass Sean Kinney – drums Additional personnel
Sources: en.wikipedia.org
In biochemistry and pharmacology, receptors are proteins that receive and transduce signals that may be integrated into biological systems. These signals are typically chemical messengers which bind to a receptor and produce physiological responses, such as a change in the electrical activity of a cell. For example, GABA, an inhibitory neurotransmitter, inhibits electrical activity of neurons by binding to GABAA receptors. There are three main ways the action of the receptor can be classified: relay of signal, amplification, or integration. Relaying sends the signal onward, amplification increases the effect of a single ligand, and integration allows the signal to be incorporated into another biochemical pathway. Receptor proteins can be classified by their location. Cell surface receptors, also known as transmembrane receptors, include ligand-gated ion channels, G protein-coupled receptors, and enzyme-linked hormone receptors. Intracellular receptors are those found inside the cell, and include cytoplasmic receptors and nuclear receptors. A molecule that binds to a receptor is called a ligand and can be a protein, peptide (short protein), or another small molecule, such as a neurotransmitter, hormone, pharmaceutical drug, toxin, calcium ion or parts of the outside of a virus or microbe. An endogenously produced substance that binds to a particular receptor is referred to as its endogenous ligand. E.g. the endogenous ligand for the nicotinic acetylcholine receptor is acetylcholine, but it can also be activated by nicotine and blocked by curare.
Protein microarrays and high throughput (HT) mass spectrometry (MS) can provide a snapshot of the proteins present in a biological sample. The former approach faces similar problems as with microarrays targeted at mRNA, the latter involves the problem of matching large amounts of mass data against predicted masses from protein sequence databases, and the complicated statistical analysis of samples when multiple incomplete peptides from each protein are detected. Cellular protein localization in a tissue context can be achieved through affinity proteomics displayed as spatial data based on immunohistochemistry and tissue microarrays.
The decay of 40K in Earth's mantle ranks third, after 232Th and 238U, in the list of sources of radiogenic heat. Less is known about the amount of radiogenic sources in Earth's outer and inner core, which lie below the mantle. It has been proposed, though, that significant core radioactivity (1–2 TW) may be caused by high levels of U, Th and K. Potassium-40 is the largest source of natural radioactivity in animals including humans. A 70 kg human body contains about 140 g (or 126 g) of potassium, hence about 140g × 0.0117% * (39.96/39.10) ≈ 16.7 mg of 40K; whose decay produces about 3,850 to 4,300 disintegrations per second (becquerel) continuously throughout the life of an adult person (and proportionally less in children). The normal potassium-40 concentration in the human body is equivalent to 55 Bq per kilogram, corresponding to an effective dose of 0.2 millisievert per year throughout the body. This is the largest source of internal radiation, followed by 0.12 mSv per year from the nuclides in the uranium and thorium decay series, and just 12 microsieverts per year from carbon-14.
1921 Research on the role of pancreas in the nutritive assimilation 1922 Frederick Banting, Charles Best and James Collip use bovine insulin extract in humans at Connaught Laboratories in Toronto, Canada. 1922 Leonard Thompson becomes the first human to be treated with insulin. 1922 James D. Havens, son of former congressman James S. Havens, becomes the first American to be treated with insulin. 1922 Elizabeth Hughes Gossett, daughter of the US Secretary of State, becomes the first American to be (officially) treated in Toronto. 1923 Dr. Trent Champion de Crespigny delivers the first treatments with insulin produced in Australia, to a 9-year-old, in Adelaide, South Australia, on 7 January 1923. 1923 Eli Lilly produces commercial quantities of much purer bovine insulin than Banting et al. had used 1923 Farbwerke Hoechst, one of the forerunners of today's Sanofi Aventis, produces commercial quantities of bovine insulin in Germany 1923 Hans Christian Hagedorn founds the Nordisk Insulinlaboratorium in Denmark – forerunner of today's Novo Nordisk 1923 Constance Collier returns to health after being successfully treated with insulin in Strasbourg 1924 Margaret Cheadle, a research biochemist in the laboratory of T. Brailsford Robertson at the University of Adelaide, determined that approx. 167 "mouse units" of insulin were "equivalent to one two-kilogram rabbit-unit". 1926 Nordisk receives a Danish charter to produce insulin as a non-profit 1936 Canadians David M. Scott and Albert M.
Sources: en.wikipedia.org
Ethylenediaminetetraacetic acid (EDTA), also called EDTA acid, is an aminopolycarboxylic acid with the formula [CH2N(CH2CO2H)2]2. This white, slightly water-soluble solid is widely used to bind to iron (Fe2+/Fe3+) and calcium ions (Ca2+), forming water-soluble complexes even at neutral pH. It is thus used to dissolve Fe- and Ca-containing scale as well as to deliver iron ions under conditions where its oxides are insoluble. EDTA is available as several salts, notably disodium EDTA, sodium calcium edetate, and tetrasodium EDTA, but these all function similarly.
Calcitriol also reduces calcium loss to urine. Per the diagram, calcitriol suppresses the parathyroid hormone gene, thus creating a negative feedback loop that combines to tightly maintain plasma calcium in a normal range of 2.1-2.6 mmol/L for total calcium and 1.1-1.3 mmol/L for ionized calcium. However, there are also vitamin D receptors in bone cells, so that with serum vitamin D in great excess, osteoclastic bone resorption is promoted regardless of PTH, resulting in hypercalcemia and its symptomology.
For the crimes of rape, sodomy, and polygamy (the last removed from a later version), the punishment was to be castration for men or rhinotomy for women. For intentional maiming, the bill specified literal eye for an eye retribution. The bill never passed, due to the combination of its perceived barbarity in some parts and perceived leniency in others. In England, the Offences within the Court Act 1541 provided for cutting off a hand as punishment for striking someone inside a courtroom. Thomas Jefferson's punishments revision bill also intended to repeal this. The punishment was abolished in England and Wales by the Offences Against the Person Act 1828. As of 2021, this form of punishment is controversial, as most modern cultures consider it to be morally abhorrent, as it has the effect of permanently disabling a person and constitutes torture. It is thus seen as grossly disproportionate for crimes less than those such as murder.
==== Transplastomic plants ==== Recently, chloroplasts have caught attention by developers of genetically modified crops. Since, in most flowering plants, chloroplasts are not inherited from the male parent, transgenes in these plastids cannot be disseminated by pollen. This makes plastid transformation a valuable tool for the creation and cultivation of genetically modified plants that are biologically contained, thus posing significantly lower environmental risks. This biological containment strategy is therefore suitable for establishing the coexistence of conventional and organic agriculture. While the reliability of this mechanism has not yet been studied for all relevant crop species, recent results in tobacco plants are promising, showing a failed containment rate of transplastomic plants at 3 in 1,000,000.
The escalating deadlock sparked international anxiety over a potential collapse of the 2022 peace framework. On April 30, 2026, the European Union issued a formal warning expressing "great concern" over the unilateral developments. The EU spokesperson demanded an "immediate de-escalation" of political tensions, warning that a return to armed conflict would have catastrophic humanitarian consequences for a population already suffering from widespread food insecurity and institutional collapse.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.